NAD+-boosting compounds enhance nitric oxide production and prevent oxidative stress in endothelial cells exposed to plasma from patients with COVID-19
Nitric Oxide · 2023
DOI: 10.1016/j.niox.2023.08.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nitric Oxide, 2023. Verfasst von Kaitlin A Freeberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, 80309, USA. Hauptthemen laut MEDLINE: NAD, COVID-19. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), induces vascular endothelial dysfunction, but the mechanisms are unknown. We tested the hypothesis that the "circulating milieu" (plasma) of patients with COVID-19 would cause endothelial cell dysfunction (characterized by lower nitric oxide (NO) production), which would be linked to greater reactive oxygen species (ROS) bioactivity and depletion of the critical metabolic co-substrate, nicotinamide adenine dinucleotide (NAD+). We also investigated if treatment with NAD+-boosting compounds would prevent COVID-19-induced reductions in endothelial cell NO bioavailability and oxidative stress. Human aortic endothelial cells (HAECs) were exposed to plasma from men and women (age 18-85 years) who were hospitalized and tested positive (n = 34; 20 M) or negative (n = 13; 10 M) for COVID-19. HAECs exposed to plasma from patients with COVID-19 also were co-incubated with NAD+ precursors nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). Acetylcholine-stimulated NO production was 27% lower and ROS bioactivity was 54% higher in HAECs exposed to plasma from patients with COVID-19 (both p 0.05 vs. control). Co-treatment with NMN produced similar results. Our findings suggest the circulating milieu of patients with COVID-19 promotes endothelial cell dysfunction, characterized by lower NO bioavailability, greater ROS bioactivity, and NAD+ depletion. Supplementation with NAD+ precursors may exert a protective effect against COVID-19-evoked endothelial cell dysfunction and oxidative stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, 80309, USA.
- Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
- Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, 80309, USA. Electronic address: matthew.rossman@colorado.edu.
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
- NIA NIH HHS
- National Institutes of Health
Zitieren
APA
Freeberg, K. A., Ludwig, K. R., Chonchol, M., Seals, D. R., & Rossman, M. J. (2023). NAD+-boosting compounds enhance nitric oxide production and prevent oxidative stress in endothelial cells exposed to plasma from patients with COVID-19. Nitric Oxide. https://doi.org/10.1016/j.niox.2023.08.003
Vancouver
Freeberg KA, Ludwig KR, Chonchol M, Seals DR, Rossman MJ. NAD+-boosting compounds enhance nitric oxide production and prevent oxidative stress in endothelial cells exposed to plasma from patients with COVID-19. Nitric Oxide. 2023. doi:10.1016/j.niox.2023.08.003
BibTeX
@article{Freeberg2023,
author = {Freeberg, Kaitlin A and Ludwig, Katelyn R and Chonchol, Michel and Seals, Douglas R and Rossman, Matthew J},
title = {NAD+-boosting compounds enhance nitric oxide production and prevent oxidative stress in endothelial cells exposed to plasma from patients with COVID-19},
journal = {Nitric Oxide},
year = {2023},
doi = {10.1016/j.niox.2023.08.003}
}
EUVIMED